1. Introduction
Across the globe, cervical cancer and preterm birth stand as two of the most devastating reproductive health burdens, deeply influencing morbidity, mortality, and long-term quality of life for women and infants alike. Although these two conditions may seem clinically distinct, a growing body of evidence reveals a surprising commonality: both are profoundly shaped by the ecology of microorganisms residing within the vagina. This introduction synthesizes findings from systematic reviews and meta-analyses to contextualize how disturbances in the vaginal microbiome alter host defenses, facilitate pathogen persistence, and influence disease trajectories.
The vaginal microbiome, a dynamic and nuanced microbial community, is pivotal to reproductive health. Under healthy conditions, this ecosystem is commonly dominated by Lactobacillus species — including Lactobacillus crispatus, Lactobacillus gasseri, and Lactobacillus jensenii — which create an inhospitable environment for pathogens by maintaining an acidic pH, producing lactic acid, hydrogen peroxide, and bacteriocins, and interacting with local immunity (Lamont et al., 2011; Ravel et al., 2011; Srinivasan & Fredricks, 2008). However, when this protective dominance erodes, a shift toward a diverse, anaerobe-rich community can occur, commonly defined as bacterial vaginosis (BV) or dysbiosis (Turovskiy, Sutyak Noll, & Chikindas, 2011; Biagi et al., 2009). Understanding these transitions is essential to unraveling the mechanisms linking microbial imbalance with pathological outcomes.
BV represents a polymicrobial condition marked by the depletion of lactobacilli and the overgrowth of anaerobic organisms such as Gardnerella vaginalis, Atopobium vaginae, Prevotella species, and other fastidious bacteria (Marrazzo, 2011; Shipitsyna et al., 2013; Srinivasan et al., 2012). Early models posited G. vaginalis as the principal agent, but more nuanced research reveals that its pathogenic influence largely stems from its ability to form resilient biofilms on vaginal epithelial surfaces, which orchestrate the co-aggregation of partner anaerobes and stabilizes dysbiotic communities (Swidsinski et al., 2005; Patterson et al., 2010). These biofilms not only resist host defenses but also produce virulence factors — including mucin-degrading enzymes, sialidases, and cytolysins — that degrade the mucosal barrier and facilitate the ascension of microbes into the upper reproductive tract (Lewis et al., 2013; Wiggins et al., 2001; Bohbot & Lepargneur, 2012).
Unlike classic infections that trigger robust inflammation, BV often persists with minimal overt inflammatory signs, a phenomenon attributed to metabolic byproducts of anaerobes, such as organic acids that impede neutrophil chemotaxis (Al-Mushrif, Eley, & Jones, 2000; Donders et al., 2002). This immunomodulatory effect further promotes microbial persistence and sets the stage for downstream complications.
Among the most clinically significant sequelae of dysbiosis are adverse reproductive outcomes. In pregnancy, subtle microbial shifts can precipitate subclinical intrauterine infections, leading to chorioamnionitis, premature rupture of membranes, and spontaneous preterm birth (PTB) — the latter being a leading cause of neonatal mortality worldwide (Di Vico et al., 2011; Ishaque et al., 2011). Organisms such as Ureaplasma urealyticum, Ureaplasma parvum, and Mycoplasma hominis have been frequently associated with preterm labor and adverse pregnancy outcomes, suggesting that dysbiosis may play a causative role beyond mere association (Capoccia, Greub, & Baud, 2013). Moreover, elevated concentrations of enzymes like sialidase and prolidase, produced by BV-associated bacteria, correlate with increased pro-inflammatory cytokines, which can trigger cascades leading to premature delivery or even stillbirth (Cauci et al., 2008; Menard et al., 2010).
Yet, the relationships are not universally uniform. Some microbial signatures, such as certain BV-associated bacteria (e.g., BVAB3), appear paradoxically linked to decreased risk of PTB, highlighting the complexity and context-dependency of vaginal microbial interactions (Africa et al., 2014). This complexity underscores the need for integrative meta-analytic approaches to disentangle which microbial patterns consistently predict adverse outcomes and which may represent benign variations.
Parallel to obstetric outcomes, the interface between the vaginal microbiome and human papillomavirus (HPV) — the necessary cause of cervical cancer — has garnered considerable research attention. Although high-risk HPV genotypes (notably HPV-16 and HPV-18) are universally recognized as the primary etiological agents of cervical cancer, microbial composition appears to influence viral persistence, clearance, and neoplastic progression (Okunade, 2020; Sung et al., 2021). Women with a Lactobacillus-dominant profile, particularly those with L. crispatus predominance, tend to clear HPV more readily, whereas communities characterized by high diversity and paucity of protective lactobacilli — often termed Community State Type IV (CST IV) — associate with higher rates of persistent infection and cervical dysplasia (Brotman et al., 2014; Ravel et al., 2011; Qingqing et al., 2021).
Mechanistically, dysbiotic communities may weaken mucosal immune defenses by reducing levels of immunoglobulins such as IgA and IgG, thereby diminishing antiviral responses at the mucosal surface (Birley, Duerden, & Hart, 2002; Nicolò et al., 2021). In addition, the metabolic milieu characteristic of dysbiosis — particularly increased L-lactic acid levels — can activate matrix metalloproteinases that compromise epithelial integrity, potentially facilitating HPV entry into basal cells and promoting viral oncogene expression (Witkin et al., 2013; Petrova, Reid, Vaneechoutte, & Lebeer, 2017). Some Lactobacillus species themselves may exert direct antiviral effects; for example, cellular supernatants from Lactobacillus demonstrate inhibitory activity against HPV oncogenes in vitro, suggesting potential protective mechanisms at multiple levels (Wang et al., 2018; Cha et al., 2012).
Across conditions, then, vaginal dysbiosis emerges not as an isolated microbial phenomenon but as a systemic modifier of host physiology — influencing immune surveillance, epithelial integrity, and susceptibility to infection and inflammation. Meta-analytic evidence indicates that women with BV-associated microbial profiles have significantly higher odds of both adverse pregnancy outcomes and persistent HPV infection, reinforcing the clinical relevance of microbiome assessment in reproductive healthcare.
Synthesizing findings across studies reveals several recurring themes. First, the protective role of Lactobacillus species — especially those that produce hydrogen peroxide — extends beyond simple colonization resistance and includes modulation of immune pathways (Lamont et al., 2011; Sgibnev & Kremleva, 2015). Second, not all dysbiotic states confer equal risk; the identity and functional properties of constituent microbes’ matter, with some organisms consistently linked to adverse outcomes and others displaying variable associations (Srinivasan et al., 2012; Fethers et al., 2012). Third, the interplay between local microbial ecology and systemic host responses suggests that both microbial and host factors should be integrated into predictive models for disease risk.
In this context, clinical implications begin to emerge. Recognizing and diagnosing dysbiotic profiles could inform risk stratification for preterm birth and cervical neoplasia. Furthermore, therapeutics aimed at restoring eubiotic conditions — through probiotics, targeted antimicrobials, or immune modulation — hold promise as adjunctive interventions. However, heterogeneity in study designs, sampling methodologies, and definitions of dysbiosis continues to complicate direct comparisons, highlighting the importance of standardized approaches in future research.
Ultimately, understanding the vaginal microbiome not as a static entity but as a dynamic ecosystem interacting with host and external factors offers a powerful lens through which to view reproductive health. Through systematic integration of microbiological, immunological, and clinical data, we gain not only mechanistic insights but also actionable pathways to improve outcomes in cervical cancer prevention and maternal–fetal medicine.